Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX)

Symphony Financial Ltd. Co. bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,000 shares of the biopharmaceutical company's stock, valued at approximately $324,000.

Several other large investors have also recently bought and sold shares of the stock. Synergy Asset Management LLC acquired a new position in shares of TG Therapeutics in the 4th quarter worth approximately $75,000. Parkwoods Wealth Partners LLC bought a new position in shares of TG Therapeutics in the fourth quarter valued at $211,000. KBC Group NV lifted its position in shares of TG Therapeutics by 48.9% during the 4th quarter. KBC Group NV now owns 6,960 shares of the biopharmaceutical company's stock valued at $209,000 after acquiring an additional 2,285 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of TG Therapeutics by 105.9% during the 4th quarter. Blue Trust Inc. now owns 3,121 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,605 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC acquired a new position in shares of TG Therapeutics in the 4th quarter worth $228,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analysts Forecast Growth

TGTX has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Wednesday, January 15th. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $40.67.

Insider Activity

In related news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares of the company's stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Stock Performance

TG Therapeutics stock traded up $0.36 during mid-day trading on Wednesday, hitting $33.27. The company had a trading volume of 731,717 shares, compared to its average volume of 2,494,490. The company has a market capitalization of $5.18 billion, a price-to-earnings ratio of -331.90 and a beta of 2.26. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company's fifty day moving average is $31.54 and its 200-day moving average is $26.74. TG Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $36.84.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analysts' expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company's quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.73 earnings per share. Equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.